Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Prognosis in women with breast cancer and private extra insurance coverage.

Grau JJ, Zanon G, Caso C, Gonzalez X, Rodriguez A, Caballero M, Biete A.

Ann Surg Oncol. 2013 Sep;20(9):2822-7. doi: 10.1245/s10434-013-3025-3. Epub 2013 Jun 11.

2.

Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study.

de Glas NA, Fontein DB, Bastiaannet E, Pijpe A, De Craen AJ, Liefers GJ, Nortier HJ, de Haes HJ, van de Velde CJ, van Leeuwen FE.

Cancer. 2014 Sep 15;120(18):2847-54. doi: 10.1002/cncr.28783. Epub 2014 May 19.

3.
4.

Patterns of care with regard to surgical choice and application of adjuvant radiation therapy for preinvasive and early stage breast cancer in rural Appalachia.

Freeman AB, Huang B, Dragun AE.

Am J Clin Oncol. 2012 Aug;35(4):358-63. doi: 10.1097/COC.0b013e3182118d27.

PMID:
21422902
5.

Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED).

Juan O, Lluch A, de Paz L, Prósper F, Azagra P, Marugán I, Martínez-Agulló A, Garcia-Conde J.

Breast Cancer Res Treat. 1999 Jan;53(2):105-12.

PMID:
10326787
6.

Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.

Fisher BJ, Perera FE, Cooke AL, Opeitum A, Stitt L.

Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):117-23.

PMID:
9747828
7.

259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.

Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A, Taffurelli M.

Breast Cancer Res Treat. 2008 Jun;109(3):405-16. Epub 2007 Aug 9. Review.

PMID:
17687650
8.

Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer.

Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez-MacGregor M, Yi M, Hunt KK, Strom EA.

Ann Surg Oncol. 2015 Jan;22(1):90-5. doi: 10.1245/s10434-014-3991-0. Epub 2014 Sep 24.

PMID:
25249256
9.

Stage 0 to stage III breast cancer in young women.

Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST.

J Am Coll Surg. 2000 May;190(5):523-9.

PMID:
10801018
10.

Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.

Peterson DJ, Truong PT, Sadek BT, Alexander CS, Wiksyk B, Shenouda M, Raad RA, Taghian AG.

Ann Surg Oncol. 2014 Oct;21(11):3490-6. doi: 10.1245/s10434-014-3767-6. Epub 2014 May 20.

PMID:
24841346
11.

Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis.

Willner J, Kiricuta IC, Kölbl O.

Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):853-63.

PMID:
9128962
12.

Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence.

Fisher BJ, Perera FE, Cooke AL, Opeitum A, Venkatesan V, Dar AR, Stitt L.

Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):541-50.

PMID:
9231678
13.

Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M.

Ann Surg Oncol. 2012 Jun;19(6):1808-17. doi: 10.1245/s10434-011-2189-y. Epub 2011 Dec 30.

PMID:
22207051
14.

Increasing use of elective mastectomy and contralateral prophylactic surgery among breast conservation candidates: a 14-year report from a comprehensive cancer center.

Dragun AE, Pan J, Riley EC, Kruse B, Wilson MR, Rai S, Jain D.

Am J Clin Oncol. 2013 Aug;36(4):375-80. doi: 10.1097/COC.0b013e318248da47.

PMID:
22643566
15.

Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?

Aurilio G, Bagnardi V, Graffeo R, Nolè F, Petit JY, Locatelli M, Martella S, Iera M, Rey P, Curigliano G, Rotmensz N, Munzone E, Goldhirsch A.

Anticancer Res. 2014 Nov;34(11):6677-83.

PMID:
25368274
16.

Prognostic significance of local recurrence in breast cancer after postmastectomy radiotherapy.

Dunst J, Steil B, Furch S, Fach A, Lautenschläger C, Diestelhorst A, Lampe D, Kölbl H, Richter C.

Strahlenther Onkol. 2001 Oct;177(10):504-10.

PMID:
11680014
17.

Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.

Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.

J BUON. 2013 Jul-Sep;18(3):585-93.

PMID:
24065468
18.

[Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].

Zhang P, Xu BH, Ma F, Li Q, Yuan P, Wang JY, Zhang P.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):381-4. Chinese.

PMID:
21875471
19.

Twenty-year outcomes after breast-conserving surgery and definitive radiotherapy for mammographically detected ductal carcinoma in situ.

Wilkinson JB, Vicini FA, Shah C, Shaitelman S, Jawad MS, Ye H, Kestin LL, Goldstein NS, Martinez AA, Benitez P, Chen PY.

Ann Surg Oncol. 2012 Nov;19(12):3785-91. doi: 10.1245/s10434-012-2412-5. Epub 2012 May 30.

PMID:
22644510
20.

Neoadjuvant chemotherapy in stage III breast cancer.

Alassas M, Chu Q, Burton G, Ampil F, Mizell J, Li BD.

Am Surg. 2005 Jun;71(6):487-92.

PMID:
16044927

Supplemental Content

Support Center